Unknown

Dataset Information

0

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer.

ABSTRACT: AIM:To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed in vitro combination studies. METHODS:We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn. RESULTS:All treatment schemes showed an antagonistic effect in all cell lines, independent of the cMET status. Despite their different genetic backgrounds, all cell lines (EBC-1, HCC827, H1975 and LUDLU-1) showed antagonistic combination indexes ranging from 1.3-2.7. These results were independent of the treatment schedule. CONCLUSION:These results discourage further efforts to combine cMET inhibition with cisplatin chemotherapy in NSCLC.

SUBMITTER: Van Der Steen N 

PROVIDER: S-EPMC5143436 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Better to be alone than in bad company: The antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer.

Van Der Steen Nele N   Deben Christophe C   Deschoolmeester Vanessa V   Wouters An A   Lardon Filip F   Rolfo Christian C   Germonpré Paul P   Giovannetti Elisa E   Peters Godefridus J GJ   Pauwels Patrick P  

World journal of clinical oncology 20161201 6

<h4>Aim</h4>To investigate the potential benefit of combining the cMET inhibitor crizotinib and cisplatin we performed <i>in vitro</i> combination studies.<h4>Methods</h4>We tested three different treatment schemes in four non-small cell lung cancer (NSCLC) cell lines with a different cMET/epidermal growth factor receptor genetic background by means of the sulforhodamine B assay and performed analysis with Calcusyn.<h4>Results</h4>All treatment schemes showed an antagonistic effect in all cell l  ...[more]

Similar Datasets

Unknown Better to Be Alone than in Bad Company: Cognate Synonyms Impair Word Learning.
| S-EPMC7463594 | biostudies-literature
Unknown CDK4/6 Inhibitors in Combination Therapies: Better in Company Than Alone: A Mini Review.
| S-EPMC9197541 | biostudies-literature
Unknown Better to Be in Bad Company than to Be Alone? Aedes Vectors Respond Differently to Breeding Site Quality in the Presence of Others.
| S-EPMC4526638 | biostudies-literature
Unknown Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models.
| S-EPMC3515409 | biostudies-literature
Unknown Crizotinib in ROS1-rearranged non-small-cell lung cancer.
| S-EPMC4264527 | biostudies-other
Unknown Amrubicin: potential in combination with cisplatin or carboplatin to treat small-cell lung cancer.
| S-EPMC3738252 | biostudies-literature
Unknown Better Alone or in Ill Company? The Effect of Migration and Inter-Species Comingling on Fascioloides magna Infection in Elk.
| S-EPMC4963109 | biostudies-literature
Unknown Crizotinib in the treatment of non-small-cell lung carcinoma.
| S-EPMC3687470 | biostudies-other
Unknown ALK inhibitors in non-small cell lung cancer: crizotinib and beyond.
| S-EPMC4215402 | biostudies-literature
Unknown Crizotinib-induced immunogenic cell death in non-small cell lung cancer.
| S-EPMC6445096 | biostudies-literature